Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2010

View Archived Issues

Czech scientists claim new substituted 6-(benzylamino) purine ribosides for asthma therapy

Acceleron Pharma's ACE-536 increases red blood cells in vivo

Exelixis patents novel PI3K-alpha/mTORC1 inhibitors

Michael J. Fox Foundation funds development of vaccine for PD

Nerviano Medical Sciences describes new inhibitors of PARP-1

FAAH inhibitor AM-3506 shows potential for treatment of hypertension

LY-2784544 inhibits V617F-mutant JAK-2 signaling and advances through clinical development

Preclinical data suggest NXD-30001 may hold promise to treat ALS

New supramolecular system presented for intracellular activation of therapeutic gold particles

Novel PI3K inhibitors discovered at Roche

Abbott divulges new inhibitors of IGF-I receptor

C3BS-GQR-1 shows promise in model of myocardial infarction

Sevikar HCT approved in Germany for treatment of high blood pressure

Vivus submits MAA to EMA for obesity treatment Qnexa

FDA to accept Chelsea Therapeutics' proposed NDA for Northera

Lilly gains florbetapir with acquisition of Avid Radiopharmaceuticals

Anavex files submission for clinical trials of ANAVEX 2-73 in AD

Cyclacel reports topline data from phase IIb APPRAISE trial of seliciclib

GSK and Theravance begin phase IIb trial of GSK-961081 in COPD

Phase III trial of INC-424 in myelofibrosis meets primary endpoint

Isotechnika and Paladin seek Canadian marketing approval for Voclera

Oxford BioMedica reports new phase I/II data on ProSavin in Parkinson's disease

AEterna Zentaris and FDA agree on SPA for Solorel

AV-101 shown to be safe in a phase I study for neuropathic pain

Peregrine Pharma treats last patient in phase II Cotara trial in GBM